Literature DB >> 22037249

Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum.

Thomas Böldicke1, Stefan Somplatzki, Galina Sergeev, Peter P Mueller.   

Abstract

Intrabodies are recombinantly expressed intracellular antibody fragments that can be used to specifically bind and inhibit the function of cellular proteins of interest. Intrabodies can be targeted to various cell compartments by attaching an appropriate localization peptide sequence to them. An efficient strategy with a high success rate is to anchor intrabodies in the endoplasmatic reticulum where they can inhibit transitory target proteins by binding and preventing them to reach their site of action. Intrabodies can be assembled from antibody gene fragments from various sources into dedicated expression vectors. Conventionally, antibody cDNA sequences are derived from selected hybridoma cell clones that express antibodies with the desired specificity. Alternatively, appropriate clones can be isolated by affinity selection from an antibody in vitro display library. Here an evaluation of endoplasmatic reticulum targeted intrabodies with respect to other knockdown approaches is given and the characteristics of various intrabody expression vectors are discussed. A step by step protocol is provided that was repeatedly used to construct intrabodies derived from diverse antibody isotypes producing hybridoma cell clones. The inactivation of the cell surface receptor neural cell adhesion molecule (NCAM) by a highly efficacious novel endoplasmatic reticulum-anchored intrabody is demonstrated.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037249     DOI: 10.1016/j.ymeth.2011.10.008

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  5 in total

Review 1.  Single domain antibodies for the knockdown of cytosolic and nuclear proteins.

Authors:  Thomas Böldicke
Journal:  Protein Sci       Date:  2017-03-24       Impact factor: 6.725

2.  A single-chain variable fragment intrabody prevents intracellular polymerization of Z α1-antitrypsin while allowing its antiproteinase activity.

Authors:  Adriana Ordóñez; Juan Pérez; Lu Tan; Jennifer A Dickens; Neda Motamedi-Shad; James A Irving; Imran Haq; Ugo Ekeowa; Stefan J Marciniak; Elena Miranda; David A Lomas
Journal:  FASEB J       Date:  2015-03-10       Impact factor: 5.191

3.  Intrabodies against the Polysialyltransferases ST8SiaII and ST8SiaIV inhibit Polysialylation of NCAM in rhabdomyosarcoma tumor cells.

Authors:  Stefan Somplatzki; Martina Mühlenhoff; Andrea Kröger; Rita Gerardy-Schahn; Thomas Böldicke
Journal:  BMC Biotechnol       Date:  2017-05-12       Impact factor: 2.563

Review 4.  Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.

Authors:  Thomas Böldicke
Journal:  Antibodies (Basel)       Date:  2022-07-18

Review 5.  Specific in vivo knockdown of protein function by intrabodies.

Authors:  Andrea L J Marschall; Stefan Dübel; Thomas Böldicke
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.